PMID- 23633273
OWN - NLM
STAT- MEDLINE
DCOM- 20160901
LR  - 20140307
IS  - 1897-4279 (Electronic)
IS  - 0022-9032 (Linking)
VI  - 72
IP  - 2
DP  - 2014
TI  - Prognostic value of serum resistin levels in patients with acute myocardial 
      infarction.
PG  - 181-6
LID - 10.5603/KP.a2013.0086 [doi]
AB  - BACKGROUND: Resistin is a novel adipokine that is suggested to be involved in 
      inflammatory conditions and atherosclerosis. AIM: To investigate the prognostic 
      importance of resistin in acute myocardial infarction (AMI) patients. METHODS: 
      Resistin levels were measured in a population of 132 patients with AMI, of whom 
      72 (54%) had a diagnosis of ST elevation myocardial infarction (STEMI), and 60 
      (46%) had non-ST elevation myocardial infarction (NSTEMI). Thirty-three 
      consecutive subjects who were referred to elective coronary angiography due to 
      chest pain evaluation with normal coronary angiograms served as controls. All 
      patients were followed-up for the occurrence of major adverse cardiac events 
      (MACE). RESULTS: There was a significant increase in serum resistin levels in 
      patients with AMI compared to controls (3.71 +/- 4.20 vs. 2.00 +/- 1.05, p = 0.001, 
      respectively). However, serum resistin levels were similar in patients with STEMI 
      and NSTEMI. (4.26 +/- 5.11 vs. 3.06 +/- 2.64, p = 0.49, respectively). The patients 
      with MACE had significantly higher levels of serum resistin levels compared to 
      either the AMI or the control group (6.35 +/- 5.47, p = 0.005, respectively). 
      Logistic regression analysis revealed that resistin, left ventricular ejection 
      fraction, and coronary artery bypass graft were independent predictors of MACE in 
      AMI patients (OR = 1.11, 95% CI 1.01-1.22, p = 0.03 and OR = 3.84, 95% CI 
      1.26-11.71, p = 0.018, respectively). CONCLUSIONS: Serum resistin level was 
      increased in patients with AMI and constituted a risk factor for MACE in this 
      group.
FAU - Erer, Hatice Betul
AU  - Erer HB
AD  - Department of Cardiology, Siyami Ersek Thoracic and Cardiovascular Surgery 
      Centre, Istanbul, Turkey. drhberer@yahoo.com.
FAU - Sayar, Nurten
AU  - Sayar N
FAU - Guvenc, Tolga Sinan
AU  - Guvenc TS
FAU - Aksaray, Sebahat
AU  - Aksaray S
FAU - Yilmaz, Hale
AU  - Yilmaz H
FAU - Altay, Servet
AU  - Altay S
FAU - Turer, Ayca
AU  - Turer A
FAU - Oz, Tugba Kemaloglu
AU  - Oz TK
FAU - Karadeniz, Fatma Ozpamuk
AU  - Karadeniz FO
FAU - Oz, Dilaver
AU  - Oz D
FAU - Ekmekci, Ahmet
AU  - Ekmekci A
FAU - Zencirci, Aycan Esen
AU  - Zencirci AE
FAU - Eren, Mehmet
AU  - Eren M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20130430
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Biomarkers)
RN  - 0 (Resistin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Biomarkers/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*blood
MH  - Prognosis
MH  - Resistin/*blood
MH  - Risk Factors
MH  - Sex Factors
EDAT- 2013/05/02 06:00
MHDA- 2016/09/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/01/28 00:00 [received]
PHST- 2013/04/23 00:00 [accepted]
PHST- 2013/02/24 00:00 [revised]
PHST- 2013/05/02 06:00 [entrez]
PHST- 2013/05/02 06:00 [pubmed]
PHST- 2016/09/02 06:00 [medline]
AID - VM/OJS/KP/7648 [pii]
AID - 10.5603/KP.a2013.0086 [doi]
PST - ppublish
SO  - Kardiol Pol. 2014;72(2):181-6. doi: 10.5603/KP.a2013.0086. Epub 2013 Apr 30.